Recent Quotes (30 days)

You have no recent quotes
chg | %

Sernova Corp.  

(Public, CVE:SVA)   Watch this stock  
Find more results for SVA
0.220
+0.010 (4.76%)
Jul 24 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.22 - 0.22
52 week 0.18 - 0.37
Open 0.22
Vol / Avg. 128,400.00/95,602.00
Mkt cap 35.06M
P/E     -
Div/yield     -
EPS -0.01
Shares 159.37M
Beta 0.05
Inst. own     -

Key stats and ratios

Q2 (Apr '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -43.55% -53.31%
Return on average equity -49.69% -60.00%
CDP Score - -

Address

700 Collip Cir Suite 114
LONDON, ON N6G 4X8
Canada
+1-519-8585184 (Phone)
+1-519-8585099 (Fax)

Website links

Description

Sernova Corp. is a development-stage regenerative medicine company. The Company is engaged in the development of its Cell Pouch and associated technologies, including therapeutic cells for the treatment of chronic diseases and local immune protection technologies. It is focused on developing a treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted and prevascularized medical device (the Cell Pouch), protected from immune system attack. The Cell Pouch is designed to create a microvessel rich, tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the treatment of chronic diseases, such as diabetes and thyroid disease. Its lead program is the clinical development of the Cell Pouch for treatment of patients with insulin dependent diabetes. It is also evaluating Cell Pouch for the treatment of patients with hemophilia A.

Officers and directors

Frank A. Holler Chairman of the Board
Age: 57
Philip Toleikis President, Chief Executive Officer
Scott Langille Chief Financial Officer
Age: 59
James T. Parsons CPA Director
Bruce Weber Director
Jeffrey A. Bacha Independent Director
Age: 48